Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

Esophageal cancer starts with subtle symptoms like trouble swallowing, heartburn, and hoarseness, but early detection is ...

Jose B. Lingad Memorial General Hospital Head and Neck Cancer Specialist Paulyn Gaddi urges the public to practice healthy ...

She now has to be checked regularly for the rest of her life to make sure the cancer doesn’t come back. She believes that because her symptoms were not the usual signs of Hashimoto’s disease, doctors ...

coli may set the stage for colon cancer later in life. Common symptoms include blood in the stool and abdominal pain, which are most often caused by more benign conditions like hemorrhoids ...

To be marked as Anniko, penpulimab is approved alongside chemotherapy for the first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma, or as a single agent in ...

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved penpulimab ...

The antibody is to treat adult recurrent or metastatic non-keratinising nasopharyngeal carcinoma (NPC) in conjunction with cisplatin or carboplatin and gemcitabine as a first-line treatment.

in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved ...

April 25, 2025 — The FDA has approved a new drug for adults with a rare type of head and neck cancer known as non-keratinizing nasopharyngeal carcinoma (NPC) after studies showed that ...

for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC); or as a single agent, for the treatment of adults with metastatic ...

in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with certain types of nasopharyngeal carcinoma (NPC), and as a single agent for certain patients ...